The installation of the CTD facility at Plankstadt is a response to customer demands and the recognition of gaps in scale, formulation development technologies for insoluble APIs
CordenPharma, a CDMO for APIs, excipients, drug products & packaging services, has announced an investment of €9.7m ($11.2m) into the design and installation of a GMP clinical trial development facility for the manufacturing of oral solid dosage drug products at its Plankstadt site located near Heidelberg, Germany.
Plankstadt is the company's site for the development & manufacturing of highly potent oral solid drug products for compounds that have an OEL level < 1 µg/m3. At this site, the company offers a range of services for HPAPI pharmaceutical development including manufacturing, packaging, and pharma-logistics.
The installation of the CTD facility at Plankstadt is a response to customer demands and the recognition of gaps in scale, formulation development technologies for insoluble APIs, and manufacturing of capsule products, the company says. Joining three other CTD sites, the facility will be designed with multi-product capability, allowing multiple projects to run in parallel. Work has recently started in the fourth quarter of 2021, with a targeted completion date in the third quarter of 2022.
“This is an extremely important and significant investment for CordenPharma Plankstadt. The new CTD 4 facility will bridge the gap between our small-scale GMP and larger commercial production facilities. It also expands our capabilities beyond coated tablets with the addition of contained-capsule filling equipment,” states Dr. Lutz Henkel, Managing Director of CordenPharma Plankstadt. “CordenPharma’s goal is to be the leading CDMO for the development and manufacturing of Highly Potent & Oncology solid dosage forms. Adding Hot Melt Extrusion to our toolbox allows us to help more customers that have solubility-limited APIs. We are excited about this investment in Plankstadt, as it strengthens our core capabilities and expands our service offerings,” said Dr Brittany Hayes, Director of CordenPharma’s Global Highly Potent & Oncology Platform.
The investment in CordenPharma Plankstadt is the latest of several announced investments made by CordenPharma during 2021, where further capacity expansion and capabilities have been installed in CordenPharma Colorado and CordenPharma Chenôve to meet growing customer demands.